Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Dec
6
2019
Scientists Uncover Production Of Aromatic Alcohols From Lignocellulosic Biomass Bergeson & Campbell, P.C.
Dec
6
2019
USDA Finalizes Rule For SNAP Requirements for Able-Bodied Adults Without Dependents Keller and Heckman LLP
Dec
5
2019
FDA Issues Swiss Company a Temporary Permit to Market “Ruby Chocolate” in the United States Keller and Heckman LLP
Dec
5
2019
TCPA Class Melts Under Sweltering Scrutiny: Company-Wide Training Policy and Plaintiff’s “Distressing” Ignorance of Her Claim Against Ice Cream Company Defeats Typicality and Adequacy Squire Patton Boggs (US) LLP
Dec
5
2019
Evolution & Revolution: Device Policy Priorities at FDA in 2019 Mintz
Dec
5
2019
Researchers Find Nanotoxicity Studies May Be Affected by Nanoparticles Staying Behind in Syringes Bergeson & Campbell, P.C.
Dec
4
2019
Year-End State Law Roundup: Get Ready for 2020! (US) Squire Patton Boggs (US) LLP
Dec
4
2019
What to Know About FDA’s Recent Statements on CBD McDermott Will & Emery
Dec
4
2019
Gov. Evers Signs Hemp 2.0 Bill von Briesen & Roper, s.c.
Dec
4
2019
Proposed Class Action Alleges Company’s CBD Products Violate Federal Law Keller and Heckman LLP
Dec
3
2019
ECHA Releases New, Updated Guidance Documents for Registering Nanoform Substances Bergeson & Campbell, P.C.
Dec
3
2019
Less Than One Month until California Online Ingredients Disclosure Requirements in Effect for Designated Cleaning Products Bergeson & Campbell, P.C.
Dec
3
2019
Governor Evers Signs Legislation Advancing Wisconsin Hemp Regulation Godfrey & Kahn S.C.
Dec
3
2019
Private Eyes: When is Company Information Shared with the CPSC Confidential? ArentFox Schiff LLP
Dec
3
2019
China Solicits Comments on Food-Contact Substances Keller and Heckman LLP
Dec
3
2019
After Decades of Broad Enforcement Discretion, FDA Signals New Approach to Homeopathic Drugs Epstein Becker & Green, P.C.
Dec
3
2019
Farmers Can Now Apply for Federal USDA Hemp Production Licenses Keller and Heckman LLP
Dec
2
2019
Illinois Legislature Clarifies Employer Liability Under Cannabis Act Barnes & Thornburg LLP
Dec
2
2019
11th Circuit Rules for Plaintiffs in Class Action Lawsuit Based on Economic Loss From Purchase of ‘Worthless’ Supplements Containing DMBA – an Impermissible NDI Keller and Heckman LLP
Dec
2
2019
Key Vote in FDA Commissioner Confirmation Process Set for December 3rd Mintz
Dec
2
2019
Key Considerations for Investments in Entities Developing Innovative FDA-Regulated Products McDermott Will & Emery
Nov
30
2019
FDA Issues Warnings to 15 Companies for Illegally Selling Products Containing CBD Ward and Smith, P.A.
Nov
28
2019
Atlantic Salmon Producers Netted by DOJ Bilzin Sumberg
Nov
27
2019
FDA Won’t Enforce Pre-Market Review Requirement for E-Liquid Packaging Modified to Incorporate “Flow Restrictors” Keller and Heckman LLP
Nov
27
2019
Senator Gillibrand Announces Bill to Expand FDA’s Investigative Authorities Keller and Heckman LLP
Nov
27
2019
Broad Genus Of HCV Compounds Wasn’t Enabled Or Described McDermott Will & Emery
Nov
27
2019
Only Director May Decide Merits Of Certificate Of Correction McDermott Will & Emery
Nov
26
2019
First Indicators of FDA’s Policy Decision on CBD and Cannabis-Derived Ingredients: “Only Limited Data” and “Real Risks” Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins